To the Editor Dr McCartney and colleagues1 evaluated the effect of a low-dose intracoronary fibrinolytic drug (alteplase) administered early after reestablishing coronary reperfusion on microvascular obstruction in patients undergoing primary percutaneous coronary intervention (PCI). Although the findings of the study did not support this mode of therapy, some aspects of the trial deserve discussion.
Sezer M, Umman S. Fibrinolytic Therapy to Reduce Microvascular Obstruction After Myocardial Infarction. JAMA. 2019;321(20):2032. doi:10.1001/jama.2019.2776
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: